Michael Huang

Michael Huang is currently the 執行合夥人 at 台杉投資 and holds board member positions at Windgap Medical, Inc., Frequency Therapeutics, Elixiron Immunotherapeutics, Point Robotics Medtech, Regenacy Pharmaceuticals, Inc., Viracta Therapeutics, Inc., and Fractyl Health. In the past, Michael served as the Chief Executive Officer of NeuroVive Pharmaceuticals Asia, Inc. and held positions at TWi Pharmaceuticals, Inc. and XCi Ventures, Inc. Huang has a Master of Business Administration in Finance from Rice University, a Master of Science in Chemistry from The University of Texas at Arlington, and a Bachelor of Science in Biochemistry from The University of Texas at Austin.